As a proof of concept, we demonstrate that a small-molecule inhibitor rationally designed against MBNL1 can preferentially kill MLL-rearranged leukemia cells while sparing normal CD34+ hematopoietic stem/progenitor cells. The gene discussed is CD34; the disease is leukemia.